Getting to the Heart of Prostate Cancer: Expanding Options to Improve Outcomes for Men of Color

When you click on "Take Course" you will be taken to MyCME.com where you can participate in the activity. 

This educational initiative will highlight the multidisciplinary approach to ensure appropriate care for patients and bring awareness to the risks of ADT. Furthermore, it will provide the resources for community practitioners, specialty providers, and patients to help identify and overcome disparities within the healthcare system.

Target Audience

Urologists, Medical Oncologists, Nurse Practitioners, Physician Assistants, Pharmacists, Nurses, and other prostate cancer advanced practice providers.

Learning Objectives

At the conclusion of this activity, participants will be able to (or better able to):

  1. Delineate clinical differences between GnRH agonists and antagonists used in different stages of prostate cancer
  2. Describe health disparities for Black men with prostate cancer and understand the prevalence of prostate cancer amongst Black men
  3. Assess the CV risk associated with ADT in patients with metastatic prostate cancer
  4. Integrate a multidisciplinary approach into treatment decisions for patients initiating ADT and novel antiandrogens for prostate cancer
Course summary
Available credit: 
  • 1.25 ACPE Pharmacy
  • 1.25 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 ANCC
    • 1.25 ANCC Pharmacology
  • 1.25 Participation
Course opens: 
05/31/2022
Course expires: 
05/31/2023

 

 

Travel

Eu sem integer vitae justo eget magna fermentum.

FACULTY

Mark Katz, MD
Program Course Director
Urology Specialist
Boston Medical Center
Assistant Professor of Urology
Boston University School of Medicine
Boston, Massachusetts

Dr. Mark Katz, CME Course Director, has no relevant financial relationships to disclose

David Hughes, PharmD, BCOP
Clinical Pharmacy Manager – Specialty Programs/Oncology
PGY2 Oncology Residency Program Director
Boston Medical Center
Assistant Professor of Medicine
Boston University School of Medicine
Boston, Massachusetts

David Hughes, PharmD, discloses that he is a speaker for Abbvie and Amgen and receives grant support from Rigel Pharmaceuticals.

CME Project Manager: Michael Burk

Alicia Morgans, MD
Genitourinary Medical Oncologist
Medical Director of Survivorship Program
Dana Farber Cancer Institute
Boston, Massachusetts

Dr. Alicia Morgans discloses that she is a consultant and speaker for Astellas, AstraZeneca, Bayer, Clovis, Dendreon, Myovant, Lantheus, Merck, Sanofi, Janssen, Novartis and Pfizer. She also receives grant and research support from Astellas, Bayer, Dendreon and Seattle Genetics.

Disclosure link: 
https://www.mycme.com/courses/prostate-cancer-options-for-men-of-color-8272

CME Accreditation

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

ANCC Accreditation

Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

CNE Contact Hours: 1.25, all of which is eligible for pharmacology credit

ACPE Accreditation

The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This is an application-based educational activity. Pharmacists will receive 1.25 contact hours (0.125 CEUS) for the educational activity. No partial credit is available.

UNIVERSAL ACTIVITY NUMBER (UAN) 0060-9999-22-048-H01-P

 

Available Credit

  • 1.25 ACPE Pharmacy
  • 1.25 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 ANCC
    • 1.25 ANCC Pharmacology
  • 1.25 Participation
Please login or register to take this course.